Ayala Corporation’s (AC) healthcare segment, Ayala Healthcare Holdings, Inc. (AC Health) has recently signed an investment agreement with SPRIM Ventures on the 31st of May. SPRIM Ventures is the parent of Fibronostics, a U.S based medical technology company. The investment was made possible through Vigos or the technology arm of SPRIM. It seems like Ayala is looking forward to expanding its business across its various segments, not just its property arm. With its investment in this U.S firm, the company expects to provide more monitoring and screening solutions in its healthcare clinics. Let’s take a look at the strong points of this recent investment.
Catch me in my live training events! (quick plug)
The heart of why I do these seminars is I want to build a generation of Filipinos with the right foundation in stock investing. I want to bring smart investing to every Filipino around the world! If you would like to know more about how you could time the market check out the trainings below.
Stock Smarts Manila — June 15, 16, 22, 23, & 29, 2019
Stock Smarts Iloilo – July 6 & 7, 2019
Stock Smarts Cagayan De Oro – July 20 & 21, 2019
Stock Smarts Hong Kong – August 11, 2019
Stock Smarts UAE – August 30 – September 3, 2019
Stock Smarts Qatar — October 3 – 6, 2019
Stock Smarts Taiwan – November 2, 2019
AC disclosed that Fibronostics is a firm that focuses on non-invasive, algorithm-based services for diagnostic testing. Basically, the goal of this medical technology firm is to upgrade the diagnosis, follow-ups, and screening process specifically for chronic diseases such as coronary heart disease, liver disease, obstructive sleep apnea, stroke, and diabetes. Per AC, their investment in Fibronostics is well-aligned with their portfolio on Vigos health technology. In fact, the firm has the first ever digital health portfolio in the country because of Vigos. The company said that they always look for something that can improve the quality of their services while empowering their doctors. And the recent technology solution that has been acquired is one of the ways that can help AC reach its goals.
Together with AC, SPRIM Ventures also look forward to reaching more patients in the country through AC Health. It’s not AC alone who finds this investment beneficial but as well as the parent of Fibronostics. Through AC’s FamilyDOC clinics, both firms are hoping to serve more patients and those who need healthcare assistants here in the Philippines, now that the number of chronic diseases is increasing. The medical technology solution will help patients monitor, as early as they can, their health so they can coordinate with their doctors to keep them in good health. It’s a good thing to know that AC is moving towards the betterment of healthcare in the country. Let’s hope this new investment would benefit us as investors and as patients at the same time.
There will be two products from Fibronostics that will be launched by AC. It will be LiverFAST and HealthFACTR. LiverFAST focuses on monitoring and screening patients for common liver diseases. It’s a better option for liver imaging and liver biopsy since this is cheaper than the usual diagnostic processes. Meanwhile, HealthFACTR focuses on the general wellbeing of the patients. This is the solution that provides an immediate risk assessment to patients and customized recommendations depending on the current medical guidelines. Surely, these two solutions will make a great difference for doctors and patients. While AC is stepping up its healthcare business, let’s not forget that as investors, health is also our wealth.